TROMSØ, NORWAY: ArcticZymes Technologies ASA (OSE:AZT) announced the appointment of Michael Akoh as its new Chief Executive Officer.
Michael Akoh is an accomplished business executive with strong leadership experience, and an established reputation in the life sciences sector. He has over 20+ years of international experience in general management, business development and commercialization within the biopharma industry, including senior roles at diagnostic, med tech and CRO companies.
Michael holds a BSc. (Econ) and a MSc. in International Marketing and Management from the Copenhagen Business School.
Michael says “I am delighted to have been appointed to lead ArcticZymes. It is a business with a global presence, a talented team and a strong reputation as an innovative supplier of novel enzymes. I look forward to engaging with the AZT team, the Board of Directors and our shareholders and to continue to build AZT into a world-class enzyme company”.
Dr Marie Roskrow, Chairman of the Board added “We are very fortunate to have engaged Michael as our next CEO. Coulter Partners ran an excellent search process and we had a number of first-class candidates to choose from.in the end, it was Michael’s leadership experience, strategic approach and enthusiasm that made him a stand-out. We welcome Michael to AZT and wish him every success”.
ArcticZymes Technologies divests Biotec BetaGlucans subsidiary to Lallemand
